BCL2 and acute lymphoblastic leukemia: In conclusion, these results demonstrate that αCD7/EVs/CytC/siBcl2 had excellent therapeutic effects on T‐ALL by enhancing antitumour effects through Bcl2 inhibition and subsequent MOMP activation.